The estimated Net Worth of Yossi Maimon is at least $806 mil dollars as of 14 December 2015. Mr Maimon owns over 10,000 units of Ayala Pharmaceuticals stock worth over $5,000 and over the last 17 years he sold AYLA stock worth over $108,842. In addition, he makes $692,182 as CFO e Sec. & Treasurer at Ayala Pharmaceuticals.
Mr has made over 9 trades of the Ayala Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of AYLA stock worth $7,800 on 14 December 2015.
The largest trade he's ever made was exercising 167,698 units of Ayala Pharmaceuticals stock on 15 October 2009 worth over $162,667. On average, Mr trades about 32,798 units every 136 days since 2008. As of 14 December 2015 he still owns at least 10,000 units of Ayala Pharmaceuticals stock.
You can see the complete history of Mr Maimon stock trades at the bottom of the page.
Yossi Maimon CPA, M.B.A., CPA, MBA is the CFO, Sec. & Treasurer at Ayala Pharmaceuticals.
As the CFO e Sec. & Treasurer of Ayala Pharmaceuticals, the total compensation of Mr MBA at Ayala Pharmaceuticals is $692,182. There are no executives at Ayala Pharmaceuticals getting paid more.
Mr MBA is 50, he's been the CFO e Sec. & Treasurer of Ayala Pharmaceuticals since . There are 3 older and 1 younger executives at Ayala Pharmaceuticals. The oldest executive at Ayala Pharmaceuticals, Inc. is Dr. Gary B. Gordon M.D., Ph.D., 68, who is the Chief Medical Officer.
Over the last 5 years, insiders at Ayala Pharmaceuticals have traded over $930,844 worth of Ayala Pharmaceuticals stock and bought 1,575,250 units worth $23,628,700 . The most active insiders traders include Growth Fund Limited Partner..., Murray A Goldberg, eGrowth Fund Limited Partner.... On average, Ayala Pharmaceuticals executives and independent directors trade stock every 37 days with the average trade being worth of $102,203. The most recent stock trade was executed by Gary B. Gordon on 24 February 2021, trading 3,000 units of AYLA stock currently worth $15,480.
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Ayala Pharmaceuticals executives and other stock owners filed with the SEC include: